[Effects of radiofrequency catheter ablation in coagulation system].
OBJECTIVE
To investigate the pathogenesis and prophylactic therapy of peripheral vascular embolism after radiofrequency catheter ablation (RFCA).


METHODS
90 patients with supraventricular tachycardia (SVT) were divided into 3 groups. Group A did not use any anticoagulant before RFCA and group B used aspirin (ASA) before RFCA, group C used calcium channel blocker-amlodipine before RFCA. Blood samples were taken at 4 time points, i.e. before and after electrophysiologic examination, immediately after RFCA and 2 days after RFCA. For each blood example, blood levels of platelet alpha-granule membrane glycoprotein-140 (Gmp-140), thromboxane B(2) (TXB(2)), protein C (PC), protein S (PS) were measured.


RESULTS
In group A, Gmp-140 and TXB(2) of the blood examples taken before electrophysiologic examination were significantly lower than those taken at the three other time points, but there was no significant change of PC and PS as compared with that at the three other time points. Ablation either on the left or right heart did not affect the levels of Gmp-140 and TXB(2); In group B and group C, the levels of Gmp-140 and TXB(2) of the samples were significantly lower than those of the corresponding points in group A.


CONCLUSIONS
It is indicated that platelet aggregability may be introduced by RFCA, but evolution of the anticoagulant system was not caused by RFCA, This may enhance the occurrence of thrombosis. ASA and amlodipine may prevent the occurrence of thrombosis.
Zeng
Q
Q
Institute of Cardiovascular Disease, Xiehe Hospital, Tongji Medical University, Wuhan 430022, China.
Qin
R
R
Zhang
G
G
Qin
C
C
Cao
L
L
Chen
Z
Z
D000293:Adolescent; D000328:Adult; D001241:Aspirin / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects / Q000528:radiation effects*; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D017115:Catheter Ablation / Q000009:adverse effects*; D004617:Embolism / Q000209:etiology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D013617:Tachycardia, Supraventricular / Q000601:surgery
D002121:Calcium Channel Blockers; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin